From sahshlatypova@substack.com
By Sasha Latypova
Pointed silence from Make America Wholesome Once more about some actual well being wins
If you homicide your clients they cease coming again……
At this time is a special occasion, as a result of I deliver you excellent news.
Did you all get current MAHA speaking factors about super-awesome “wins” in well being? I’m positive you all heard issues like CDC modified their web site language about autism and vaccines? Don’t neglect that CDC phrase salads merely push bacon bits to 1 aspect of the bowl whereas crumbled cheese goes to the other finish of their web site. That means they keep “balanced and authoritative” about sciency-science. It’s the identical tactic utilized by Malone & Co: “mRNA unhealthy” from one aspect of the mouth, and “RSV shot for each new child now” from the opposite aspect. I’m uninterested in this whack-a-mole. Simply do not forget that phrases on authorities web sites and out of deep staters’ mouths are meaningless distractions.
You’ll be able to test what MAHA is at present instructing their digital seals to clap about right here. I get their reps consistently in my feedback wagging fingers at me and telling me to be “supportive of Bobby”. I’m lots supportive, no worries, I simply refuse to name a 70 yo man “Bobby”. I’m, in truth, doing my half in “restoring belief in public well being” by stating the fixed stream of lies coming from it. Step one to restoration shouldn’t be not patting your self on the again however admitting you may have an issue.
The hyperlink on MAHA Motion web site for “MAHA wins” now factors to the HHS web site with numerous meals stuffs vomited forth by Calley Means, CIA brokers, assorted deep state fairies, AI algorithms and pharma lobbyists. It has some good issues like promoting the terrible toll of autism on society, however not a single phrase about vaccine harms that are extensively nicely documented in peer evaluation and in HHS’s personal information. That, you see, has to attend indefinitely, till “gold-standard science” occurs, as I’m being advised by the digital MAHA seals. You simply have to imagine! In $cienceTM!
Okay, sufficient of this.
As my title says, pointed silence needs to be examined as carefully, in truth extra carefully, than very loud bangs on social media. Let’s take a look at what MAHA appears to be cleverly NOT excited by promoting as “wins”. And there are some actually good wins as I focus on beneath. One ought to ask, why not take credit score for this?
Let’s take a look at some nice information:
CSL to maintain promoting mRNA Covid vaxxes in Asia and Europe
Arcturus indefinitely delays Covid [self-amplifying RNA] vaccine submitting: Citing “the sudden modifications in regulatory necessities by the FDA for Covid-19 vaccines,” the biotech stated its US BLA for Kostaive can be placed on maintain for the foreseeable future. The biotech stated it anticipated its associate CSL to maintain promoting the shot in Asia and Europe. Final month, it emerged that the FDA requested for extra medical information on the mRNA vaccine.
I wrote about Arcturus saRNA vaccine right here. They’re now shelving this product for the US indefinitely. The actual purpose – they most likely can’t get anybody lured into their “medical trials”. The full morons are already jabbed to demise, the subsequent degree up are nervous AF, the degrees above which might be… nicely, neglect it, these folks can learn and typically do learn the “vaccine info sheets” which might be shoved in entrance of them within the faux knowledgeable consent rituals. I take this as a serious win.
Additionally: Moderna is essentially the most shorted inventory in S&P 500 as most Individuals are saying no to the jabs.
Subsequent excellent news:
CRISPR Therapeutics cabinets CD70 CAR-T program: The gene modifying biotech was growing an off-the-shelf CAR-T remedy referred to as CTX131 for strong and blood cancers in Section 1 trials. CRISPR stated that it “strategically redirected assets away from this program” in favor of different applications with higher “worth creation” potential.
Translation: that is pharmaspeak for “I wish to spend extra time with my household”. Concerning CAR-Ts, I’ll most likely write some extra about them sooner or later, however suffice to say for now – that is one other chemical poison cocktail which you’re taking after your total bone marrow will get wiped by chemo… to provide the “right antibodies”! Sounds heavenly, as within the pearly gates await…
Subsequent, Moderna struggles to promote its vaccines, posts paltry RSV gross sales in third quarter:
Moderna posted $1 billion in third-quarter income, down 45% from the identical interval a yr in the past, as shrinking vaccine uptake and a continued incapacity to crack into the RSV market posed main challenges.
Because of this, the corporate stated it would shrink the highest finish of its 2025 income steerage by $200 million. Web gross sales had been $973 million, nearly all of which got here from Covid-19 merchandise.
Solely $2 million in RSV vaccine gross sales had been reported, a sliver of the a whole lot of tens of millions of {dollars} posted by Pfizer and GSK, the primary entrants available in the market. Since Moderna’s RSV product was authorised in Could 2024, it hasn’t but eclipsed $30 million in whole gross sales.
Nicely, what can I say? If you homicide your clients they cease coming again. Who might have predicted this…
All vaccine gross sales are down, together with the flu vaccines. It’s as a result of RFK Jr says unhealthy issues about them, no different purpose (like, for instance, killing and injuring folks?):
Nicely into the primary chilly and flu season with Robert F. Kennedy Jr. as chief of HHS, vaccine income and uptake are down whereas federal well being officers proceed to scrutinize their worth.
Following third-quarter earnings, the overall consensus amongst vaccine makers for Covid-19, flu and RSV is that dampening demand has shrunk gross sales. Moderna’s internet product gross sales fell nearly 50% within the newest quarter in comparison with 2024. Pfizer equally recorded a 19% drop in gross sales of its Covid-19 vaccine, Comirnaty, within the third quarter.
Flu vaccine makers haven’t fared any higher. GSK noticed a 24% decline in its flu portfolio within the third quarter, and Sanofi reported double-digit proportion declines.
My remark: he-he-haw-haw… I take credit score, and my readers ought to take credit score, too.
Merck buys Cidara for $9B after $339+ BARDA award. I wrote about Cidara and their “flu shot which isn’t a vaccine, we swear” right here. To worth this idiotic chemical cocktail that hasn’t even accomplished Section 3 at $9B is … stunningly silly. However okay, I don’t cry when these guys flush their cash down the bathroom. It might be that Susie Wiles promised Merck “avian flu pandemic for actual in 2026-2027” and that this time they would be the chief of the Operation Warp Pace Once more (OWSA, pronounced in Russian as “ovtza” = sheep). In any other case, I’m actually perplexed on the valuation of this rubbish with zero market potential at these stratospheric costs.
Merck’s issues deserve particular point out. They’ve been on a $19B drunken gambler procuring spree recently, together with the Cidara buy talked about above. That spree reeks of desperation as a result of for all sensible functions, Merck is a 1-trick pony, maybe 1.5-trick pony: Keytruda and Gardasil
The horse is about to expire of methods and die…
Gardasil, which represents the second largest income stream for Merck is falling off the cliff:
- In This fall 2024, Gardasil gross sales dropped 17% (year-over-year) to $1.55 billion, primarily due to weak China demand. MarketBeat
- In Q1 2025, Merck reported a 41% decline in Gardasil gross sales vs Q1 2024: Q1 2025 Gardasil got here in at $1.33B. Buyers
- For the primary half of 2025, Merck says Gardasil gross sales had been $2.45B, down 48% YoY. Zacks
Hilariously, Merck blames China! Duh. It’s all the time China’s fault:
- Merck cites “elevated strain on discretionary shopper spending … together with throughout the vaccine area” as a part of the demand weak spot for Gardasil. Pharmaceutical Commerce
- Within the U.S., Merck notes increased demand in public sector shopping for and favorable pricing dynamics for Gardasil. Merck.com
Word: it’s not the people who find themselves lining up for Gardasil within the US, it’s the federal government, particularly present Trump administration sending taxpayers’ cash to Merck and paying increased costs for his or her poison. In different phrases, a bail-out by one other title. For now.
Merck’s largest income supply, most cancers poison Keytruda will go off patent shortly:
- Merck’s SEC filings point out {that a} compound patent for Keytruda is anticipated to run out in December 2028. SEC
- The 12-year biologic exclusivity (underneath U.S. regulation for biologics) is usually cited in analyses; some sources counsel it could expire round September 2026, although patent safety continues longer. Patsnap Eureka
- Merck’s Protection: Merck is proactively launching a subcutaneous model of Keytruda (“Keytruda Qlex”) to keep up market share forward of biosimilar competitors. Chemical & Engineering Information
Merck shouldn’t be the one Large Pharma firm on an insane and slightly determined procuring spree, shopping for shit that can by no means work at astronomical valuations.
Novartis was the only real bidder for a “gene remedy” startup in Duchenne’s muscular dystrophy (over-crowded with earlier gene remedy failures), but managed to bid towards themselves a number of occasions and hike up the value they finally agreed to pay:
…4 months of negotiations and 4 hiked proposals for Novartis and Avidity Biosciences to come back to their $12 billion settlement in October, in line with a Monday monetary submitting with the background of 2025’s second-largest biopharma acquisition.
Avidity is one other poison cocktail of mRNA that, at finest, will generate $20M from 5 sufferers in income and shut down like all of the earlier failures on this “extremely uncommon” sector. No one, besides Novartis CEO and enterprise growth execs, is that silly anymore.
The primary-largest and thus stupidest deal of the yr was inked by Johnson & Johnson $14.6 billion takeover of Intra-Mobile Therapies, one other gene remedy maker. This was one other non-competitive acquisition, in any case different potential acquirer corporations stated no. However then, look what occurs:
On Jan. 6, Intra-Mobile’s bankers at Centerview and Jefferies did a fast test to see if three different corporations can be excited by buying the biotech. Inside two days, all three counterparties stated they weren’t excited by shopping for Intra-Mobile, in line with the SEC submitting.
It took one month for Johnson & Johnson to safe its $14 billion acquisition of Intra-Mobile Therapies, in line with new securities filings that shed gentle into the back-and-forth talks behind the most important biotech buyout of the previous 14 months.
It’s fairly potential that these over inflated non-competitive mega acquisitions are a type of cash laundering. Which brings me to the worldwide information.
Lastly, in worldwide information, French authorities urgently want cash for hookers and blow this vacation season and have begun raiding their accomplices in pharma. I like when this occurs. Sanofi HQ is raided by French tax inspectors.
French authorities raided Sanofi’s headquarters in Paris on Tuesday as a part of a probe into alleged tax fraud involving a number of corporations. A Sanofi spokesperson confirmed that the authorities made a go to to its headquarters, including that it’s associated to an acquisition it made greater than a decade in the past.
This completes my wrap up of fine information and wins that we needs to be celebrating. Talking out issues. Folks might not present outwardly that they hear us, and the social media platforms attempt extraordinarily exhausting to suppress us, however I hope these information factors converse for themselves. We’re being heard and the message is clearly touchdown.
